From the Clinical Knowledge Center

The Use of Antipsychotics in Patients with Dementia

Up to 15% of adults aged over 65 are diagnosed with a form of dementia, the most prevalent of which is Alzheimer’s disease (AD). AD currently affects around 4.5 million Americans, and with nearly 100,000 deaths annually, it is the fourth leading cause of mortality in the United States. September 21st was World Alzheimer’s Day and one of the many issues surrounding the management of this disorder is the use of antipsychotics in those affected...

> Read entire article
> Back to top

Compass Questions™

> Back to top

Responses from Last Compass Questions™

In the 09.09.08 issue of Clinical Compass™, we asked two questions.

Question #1 was "Do you feel confident in your ability to treat bipolar depression?" and the neuroscienceCME learning community responded:
69% - Yes
31% - No

Question #2 was "What is your current treatment choice for bipolar depression?" and the neuroscienceCME learning community responded:
21% - Olanzapine/fluoxetine combination
13% - Quetiapine
32% - Lamotrigine
20% - Lithium
14% - Other

> Back to top

New neuroscienceCME Journal Club
Premieres October 6, 2008!

Adherence and Early Predictors of Response: Tools for Individualizing Treatment in Schizophrenia

Premiere Date: Monday, October 6, 2008
Credit Expiration Date: Tuesday, October 6, 2009

Live Interaction with Experts on Featured Articles!
October 6, 2008, 12:00 - 12:45 PM ET (Marder/Green)
October 27, 2008, 12:00 - 12:45 PM ET (Harvey/Green)
November 24, 2008, 12:00 - 12:45 PM ET (Kane/Green)
Be advised that participation in the bonus Q&A sessions does not constitute additional credit or Live ACPE credit

Activity Goal
To provide mental healthcare practitioners with the most recent data and clinical implications related to optimizing maintenance therapy in schizophrenia.

Learning Objectives
At the end of this CE activity, participants should be able to:

• Discuss the implications of differential efficacy and tolerability of antipsychotics on medication adherence.
• Identify targeted behavioral approaches to improving treatment adherence in patients with schizophrenia.
• Describe early predictors of response to antipsychotic medication in patients with schizophrenia.

Credit Information
This activity offers CE credit for:

• Physicians (ACCME/AMA PRA Category 1)
• Nurses (CNE)
• Pharmacists (ACPE)
• Psychologists (APA)
• Social Workers (NASW)
• Certified Case Managers (CCMC)

All other clinicians will either receive a CME Attendance Certificate or may choose any of the types of CE credit being offered.

> View activity details
> Register now
> Back to top